Dr. Clay Siegall is the president and CEO of a renowned firm by the name Seattle Genetics. He founded this company in 1998, and he is a holder of Bachelor of Science degree in zoology from the Maryland University and a Ph.D. holder from the University of George Washington. Seattle Genetics is a significant player in the field of cancer research. Interestingly, Clay believes that the old methods of cancer treatment that required administration of brutal treatment regiments need replacement with very effective modern treatment regiments that are less harmful to the patient.
Dr. Clay Siegall venture into his career was not accidental, but it got highly motivated by the pain of watching one of his relatives struggle with cancer and nearly succumbing to death. The great pain experienced by the family member was mostly due to the treatments administered. It made him want to improve the tools of cancer treatment, and for sure he was determined to bring a solution through enhancing treatments given to patients. Dr. Clay Siegall thus dedicated his life towards research in is trying to improve the therapies used to treat cancer and succeeded in reducing the harmful effects they had on patients. The treatment regiments were now easy to administer with less adverse effects.
Seattle Genetics company has several ways of making money which include the sale of drugs, proceeds from production partnerships and giving licenses for the use of processes and technologies they have developed. His journey to success was not smooth as he almost gave up in 1999 and 2000 when they had nearly exhausted their operational capital. However, his workaholic nature saved him as he had no much time to focus on the woes affecting his business. The company also has a well-experienced staff well rooted in biotech and smart in business matters.
Other than referrals, this company has a unique marketing strategy which includes long meeting and a lot of negotiations enabling them to make deals worth 7 to 8 figures. Generally, Clay attributes his success to hard work. In 2014, he was appointed a member of Directors Board of Ultragenyx Pharmaceutical. He also worked with Bristol-Myers Squibb and National Cancer Institute before he founded Seattle Genetics in 1988.